Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Additional presentations to focus on liquid biopsy– MRD based detection and genomic profiling across solid tumorsNeoGenomics, I...
NeoGenomics (NASDAQ:NEO) affirms FY2025 Adj EPS guidance from $0.08-$0.12 to $0.08-$0.12 vs $0.09 analyst estimate..
NeoGenomics (NASDAQ:NEO) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $0.02 by 4...
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today annou...
Adhishthana.com analysis shows NeoGenomics has chosen the blue pill, consolidation likely to last until August 2026.
TD Cowen analyst Dan Brennan maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $10 to $12.
Stephens & Co. analyst Mason Carrico maintains NeoGenomics (NASDAQ:NEO) with a Overweight and raises the price target fr...
